Cost-effectiveness analysis of irinotecan+5FU/FA as first-line therapy in advanced colorectal cancer.

被引：0
|
作者：
Schmitt, C
Levy-Piedbois, C
Frappé, M
Durand-Zaleski, I
Gruia, G
Alakl, M
Rougier, P
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Aventis Pharma, Antony, France
[3] Hop Henri Mondor, Dept Publ Hlth, F-94010 Creteil, France
[4] Inst Gustave Roussy, Dept Publ Hlth & Informat, Villejuif, France
[5] Phoenix Int, MDS Pharma Serv, Sevres, France
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal hormone-receptor positive advanced breast cancer.
    Sobocki, P.
    Borgstrom, F.
    Kasteng, F.
    Paulsson, T.
    Lidgren, M.
    Henriksson, R.
    Lundkvist, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S230 - S230
  • [22] Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Li, Yan
    Liang, Xueyan
    Li, Huijuan
    Yang, Tong
    Guo, Sitong
    Chen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
  • [24] COST-EFFECTIVENESS ANALYSIS OF CETUXIMAB AND PANITUMUMAB AS FIRST-LINE THERAPIES FOR METASTATIC COLORECTAL CANCER IN SPAIN
    Moreno, V
    Martinez-Amores, B.
    Barriuso, J.
    Mezquita, L.
    Ibanez de Caceres, I.
    Ayuso, A.
    Pena, J. M.
    Perona, R.
    Grande, E.
    Belda-Iniesta, C.
    VALUE IN HEALTH, 2012, 15 (07) : A421 - A422
  • [25] Cost-effectiveness analysis of cetuximab and panitumumab as first-line metastatic colorectal cancer therapies in Spain
    Moreno, Victor
    Martinez-Amores, Brezo
    Barriuso, Jorge
    Mezquita, Laura
    Ibanez de Caceres, Inmaculada
    Ayuso Sacido, Angel
    Maria Pena, Jose
    Perona, Rosario
    Belda-Iniesta, Cristobal
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] First-line therapy for advanced colorectal cancer
    de Gramont A.
    Tournigand C.
    Louvet C.
    Maindrault-Goebel F.
    André T.
    Current Oncology Reports, 2005, 7 (3) : 167 - 172
  • [27] Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
    Munenobu Kashiwa
    The European Journal of Health Economics, 2024, 25 : 459 - 470
  • [28] Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
    Kashiwa, Munenobu
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (03): : 459 - 470
  • [29] FDA approves irinotecan as first-line therapy for colorectal cancer
    不详
    ONCOLOGY-NEW YORK, 2000, 14 (05): : 652 - +
  • [30] Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer
    Berry, Kristin
    Bensink, Mark Eliot
    Musa, Zahra
    Shankaran, Veena
    Lin, Edward H.
    Ladabaum, Uri
    Bodnar, Carolyn
    Birt, Michael
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345